Replies to post #100023 on Biotech Values

[DewDiligence]

An argument based on the FDA’s sharing of purportedly confidential data will be hard to press insofar as Lovenox is no longer protected by a valid US patent, nor is it protected by Hatch-Waxman exclusivity for any indication.